Rose Bengal inhibits [beta]-amyloid oligomers-induced tau hyperphosphorylation via acting on Akt and CDK5 kinases

• Published in: Psychopharmacology 2022-11, Vol.239 (11), p.3579
• Main Authors: Mou, Chen-Ye, Xie, Yan-Fei, Wei, Jia-Xin, Wang, Qi-Yao, Le, Jing-Yang, Bao, Yong-Jie, Zhang, Pan-Pan, Mao, Yue-Chun, Huang, Xing-Han, Pan, Han-Bo, Naman, C. Benjamin, Liu, Lin, Liang, Hong-Ze, Wu, Xiang, Xu, Jia, Cui, Wei
• Format: Article
• Language: English
• Subjects: Alzheimer's disease; Care and treatment; Development and progression; Drug therapy; Health aspects; Oligomers; Phosphorylation; Physiological aspects; Protein kinases; Stains and staining (Microscopy); Tau proteins; Testing
• ISSN: 0033-3158
• DOI: 10.1007/s00213-022-06232-3

Rationale Tau hyperphosphorylation and aggregation is considered as a main pathological mechanism underlying Alzheimer's disease (AD). Rose Bengal (RB) is a synthetic dye used for disease diagnosis, which was reported to inhibit tau toxicity via inhibiting tau aggregation in Drosophila. However, it was unknown if RB could produce anti-AD effects in rodents. Objectives The research aimed to investigate if and how RB could prevent [beta]-amyloid (A[beta]) oligomers-induced tau hyperphosphorylation in rodents. Methods and results RB was tested in vitro (0.3-1 [mu]M) and prevented A[beta] oligomers-induced tau hyperphosphorylation in PC12 cells. Moreover, RB (10-30 mg/kg, i.p.) effectively attenuated cognitive impairments induced by A[beta] oligomers in mice. Western blotting analysis demonstrated that RB significantly increased the expression of pSer473-Akt, pSer9-glycogen synthase kinase-3[beta] (GSK3[beta]) and reduced the expression of cyclin-dependent kinase 5 (CDK5) both in vitro and in vivo. Molecular docking analysis suggested that RB might directly interact with GSK3[beta] and CDK5 by acting on ATP binding sites. Gene Ontology enrichment analysis indicated that RB might act on protein phosphorylation pathways to inhibit tau hyperphosphorylation. Conclusions RB was shown to inhibit tau neurotoxicity at least partially via inhibiting the activity of GSK3[beta] and CDK5, which is a novel neuroprotective mechanism besides the inhibition of tau aggregation. As tau hyperphosphorylation is an important target for AD therapy, this study also provided support for investigating the drug repurposing of RB as an anti-AD drug candidate.